Contents

25 January 2012
Vol 4, Issue 118

About The Cover

Cover image expansion

ONLINE COVER Gut Reaction. Shown is an immunohistochemical stain of a duodenum in a teplizumab-treated humanized mouse. Teplizumab is a monoclonal antibody to CD3 being tested in clinical trials for type 1 diabetes. Waldron-Lynch et al. show that human lymphocytes (brown) migrate to the small intestine when treated with teplizumab but not control Ig. These cells then produce the immunoregulatory cytokine interleukin-10 (IL-10), and intestinal homing is critical for the treatment effects of teplizumab. A similar population of IL-10-producing cells was also observed in type 1 diabetes patients treated with teplizumab. [CREDIT: F. WALDRON-LYNCH, YALE UNIVERSITY SCHOOL OF MEDICINE]